James Quinn

Professor of Emergency Medicine, Emeritus

Academic Appointments

Professor Emeritus-Hourly, Emergency Medicine

Administrative Appointments

Medical Informatics, Stanford Hospitals and Clinics (2006 - 2008)
Co-Chair IRB Administrative Panels, Stanford University (2018 - Present)
Stanford IRB, Stanford University (2006 - Present)
Research Director, Stanford University, Division of Emergency Medicine (2004 - 2015)

Honors & Awards

Best Pediatric - Critical Care Presentation, Society of Academic Emergency Medicine (1992)
PSI Research Award, Faculty of Medicine University of Ottawa (1992)
Best Resident Publication, Annals of Emergency Medicine (1993)
Best Presentation by a Young Investigator, Society of Academic Emergency Medicine (1997)
Emergency Medicine Residency Teaching Award, University of Michigan (1998)
A Network of Research Units to Study Clinical Wound Care - 1K23AR02137, National Institutes of Health (2000)
Quarterly Bedside Teaching Award, Stanford Emergency Medicine (2003)
OTL Award, Stanford University (2005)
Quarterly Bedside Teaching Award, Stanford Emergency Medicine (2006)
Top Reviewer, Academic Emergency Medicine (2006)
Predicting High Risk Wounds in Emergency Departments – NIH R21 AR054503, National Institutes of Health (2007)
Stanford Hub for Neurological Emergency Treatment Trials – NIH U10 NS058929, National Institutes of Health (2007)
Top Reviewer, Annals Internal Medicine (2009)
Stanford Hub for Neurological Emergency Treatment Trials – NIH U10 NS058929, National Institutes of Health (2012)
Top Reviewer, Annals Internal Medicine (2014)
Top Reviewer, Annals Internal Medicine (2015)

Boards, Advisory Committees, Professional Organizations

Member, Society for Academic Emergency Medicine (1990 - Present)
Assistant Team Physician, Ottawa Senators (NHL) and Ottawa Roughriders (CFL) (1992 - 1996)
Reviewer, Academic Emergency Medicine, Pediatrics, Clinical Journal of Sport Medicine, Physician and Sports Medicine, Annals of Emergency Medicine, Journal of American Medical Association, Annals of Internal Medicine, Archives of Internal Medicine, Journal of Adhesion Science and Technology (1992 - Present)
Associate Team Physician, Ottawa Lynx/Montreal Expo AAA Affiliate Baseball Club (1994 - 1996)
Fellow, American College of Emergency Physicians (1996 - Present)
Member, HemoDynamics Inc: Medical Advisory Board (1998 - 2000)
Chair, SAEM Grants Committee (2000 - 2002)
Member, Cyance Medical: Medical Advisory Board (2000 - 2002)
Member, American Society for Testing and Materials - ASTM Tissue Adhesive Testing Task Force – F04.15.16 (2001 - 2004)
Member, AHRQ: Task Force On Emergency Department Overcrowding (2002 - 2003)
Member, R-01 Review Committee, NIAMS (2002 - 2004)
Member, Emergency Clinical Trials Network Feasibility Committee – NINDS (2003 - 2005)
Member, American College of Emergency Medicine – Clinical Policy Sub Committee on Syncope (2006 - 2007)
Member, Neurological Emergencies Treatment Trials – Steering Committee (2006 - 2017)
Member, Sapheon Therapeutics – Medical Advisory Board (2008 - 2012)
Member, iRhythm Technologies – Medical Advisory Board (2009 - Present)
Organizing Committee, FDA: Tissue Adhesive Symposium (2011 - 2011)
Clinical Advisory Board, Optmed Inc (2011 - Present)
Member, International Consortium to Standardize ED Syncope Risk Stratification (SYNERGI) Reporting (2012 - Present)
Organizing Committee, International Symposium on Syncope: Gargnano, Italy (2013 - 2013)
Organizing Committee, 2nd International Symposium on Syncope - Palermo Italy (2016 - 2017)
Clinical Advisor, Ceribell Inc (2017 - Present)

Professional Education

Certification, College of Family Physicians of Canada, Family Medicine/Emergency Medicine (1992)
Diplomat, Canadian Academy of Sport Medicine, Sport Medicine (1994)
MS, Stanford University, Health Services Research (2002)
Residency, University of Ottawa, Emergency Medicine (1992)
MD, University of Western Ontario, Medicine (1989)

Current Research and Scholarly Interests

Dr. Quinn's primary focus is emergency care research with previous experience running large multi-center trials.. He has an extensive research background in clinical decision making involving patients with syncope and in the development and clinical evaluation of tissue adhesives. He is currently focused on the use of machine learning and artificial intelligence algorithms to augment physician decision making and personalizing the care of patients.

Clinical Trials

Convalescent Plasma in Outpatients With COVID-19 Not Recruiting
More
The overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunization.The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration. This study will enroll adults presenting to the emergency department (ED) with mild, symptomatic, laboratory-confirmed COVID-19 illness, who are at high risk for progression to severe/critical illness, but who are clinically stable for outpatient management at randomization.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Vitamin C, Thiamine, and Steroids in Sepsis Not Recruiting
More
The VItamin C, Thiamine And Steroids in Sepsis (VICTAS) Study is a double-blind, placebo-controlled, adaptive randomized clinical trial designed to investigate the efficacy of the combined use of vitamin C, thiamine and corticosteroids versus indistinguishable placebos for patients with sepsis. The objective of this study is to demonstrate the efficacy of combination therapy using vitamin C, thiamine and corticosteroids in reducing mortality and improving organ function in critically ill patients with sepsis.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, 408-460-5885.
Lead Sponsor
Stanford Investigators
- James Quinn
View full details
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Not Recruiting
More
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites. The study hypotheses are that treatment of hyperglycemic acute ischemic stroke patients with targeted glucose concentration (80mg/dL - 130 mg/dL) will be safe and result in improved 3 month outcome after stroke.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, (650) 721-2645.
Lead Sponsor
Stanford Investigators
View full details
Established Status Epilepticus Treatment Trial Not Recruiting
More
The primary objective is to determine the most effective and/or the least effective treatment of benzodiazepine-refractory status epilepticus (SE) among patients older than 2 years. There are three active treatment arms being compared: fosphenytoin (FOS),levetiracetam (LEV), and valproic acid (VPA). The second objective is comparison of three drugs with respect to secondary outcomes. The final objective is to ensure that the trial is informative for treatment of established SE in children by describing the effectiveness, safety, and rate of adverse reactions of these drugs in children.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, 650.721.2645.
Lead Sponsor
Stanford Investigators
- Peter D'Souza
- James Quinn
View full details
The Use of Prophylactic Antibiotics In the Management of Dog Bites Not Recruiting
More
This double blinded RCT will help to ascertain the usefulness of prophylactic antibiotics in the management of uncomplicated dog bites, utilizing currently best available antibiotics (Augmentin) and an important clinical outcome of infection. By enrolling 100-150 patients in this pilot trial as part of a k-award the investigators plan to utilize the point estimates of infection, side effects and other important outcomes and incorporate these into a cost most to determine the most cost effective management of these wounds and to determine if further study is warranted based on the findings.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .

Lead Sponsor
- Stanford University
Stanford Investigators
- James Quinn
View full details
Albumin in Acute Ischemic Stroke Trial Not Recruiting
More
The goal of the trial is to determine whether human albumin, administered within 5 hours of symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, 6507212645.
Lead Sponsor
Stanford Investigators
- James Quinn
View full details
Progesterone for the Treatment of Traumatic Brain Injury III Not Recruiting
More
The ProTECT study will determine if intravenous (IV) progesterone (started within 4 hours of injury and given for a total of 96 hours), is more effective than placebo for treating victims of moderate to severe acute traumatic brain injury.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, 6507212645.
Lead Sponsor
Stanford Investigators
View full details
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial Not Recruiting
More
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale [NIHSS] score less than or equal to 3). TIAs are common [25], and are often harbingers of disabling strokes. Approximately 250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8 years [32], there are approximately 2.4 million TIA survivors. In a national survey, one in fifteen of those over 65 years old reported a history of TIA [33], which is equivalent to a prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed transient neurological events, the true incidence of TIA may be twice as high as the rates of diagnosis [33]. Based on our review of the National Inpatient Sample for 1997-2003, there were an average of 200,000 hospital admissions for TIA each year, with annual charges climbing quickly in the period to $2.6 billion in 2003. Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, (650) 721-2645.
Lead Sponsor
Stanford Investigators
- Nirali Vora
- James Quinn
View full details
Antihypertensive Treatment of Acute Cerebral Hemorrhage-II Not Recruiting
More
The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset. 2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months. 3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans. 4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, (650) 721-2645.
Lead Sponsor
Stanford Investigators
View full details
Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications Not Recruiting
More
The goal of this non-inferiority trial is to determine which type of routine care is the best for paramedics to stop someone from seizing.

Stanford is currently not accepting patients for this trial. For more information, please contact Rosen Mann, 6507212645.
Lead Sponsor
Stanford Investigators
- James Quinn
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Surgery
  SURG 299 (Aut, Sum)
- Graduate Research
  SURG 399 (Aut, Sum)
- Graduated Research
  EMED 399 (Spr)
- Medical Scholars Research
  EMED 370 (Win, Spr)
- Medical Scholars Research
  SURG 370 (Aut, Sum)
- Undergraduate Research
  EMED 199 (Win)
- Undergraduate Research
  SURG 199 (Aut, Sum)

All Publications

Profiles With Related Publications

close
Kanwaljeet S. Anand

Professor of Pediatrics (Pediatric Critical Care) and of Anesthesiology, Perioperative and Pain Medicine
Clinical Focus
Pediatric Critical Care Medicine

247 Total Publications
close
Steven Asch

Professor of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy
Research Interests
Describe your current research interest and activities

597 Total Publications
close
Andra Leah Blomkalns

Redlich Family Professor
Clinical Focus
Emergency Medicine, Technology Development, Clinical Innovation

92 Total Publications
close
Aaron J. Dawes, MD, PhD, FACS, FASCRS

Assistant Professor of Surgery (General Surgery)
Clinical Focus
Colon and Rectal Surgery Specialty, Colon Cancer, Rectal Cancer, Inflammatory Bowel Diseases, General Surgery

46 Total Publications
close
Dr Michael Gisondi

Professor of Emergency Medicine (Adult Clinical/Academic)
Clinical Focus
Emergency Medicine

124 Total Publications
close
Prasanthi Govindarajan

Associate Professor of Emergency Medicine
Clinical Focus
Emergency Medicine, Stroke, Emergency Medical Services, Health Services Research, Neurologic emergencies
Research Interests
My current research focuses on using large databases to understand the effect of state or county-wide public policy on health care outcomes (specifically stroke). Our team is also exploring how patient safety, effective and equitable care in acute stroke management can be achieved using technology.

40 Total Publications
close
Mary Hawn, MD, FACS

Emile Holman Professor of Surgery
Clinical Focus
General Surgery, Gastroesophageal Reflux Disease, Achalasia, Hiatal Hernias, Gallbladder Disease, Hernias

230 Total Publications
close
Paul Heidenreich, MD

Professor of Medicine (Cardiovascular)
Clinical Focus
Echocardiography, Cardiovascular Disease
Research Interests
My research interests include

1) The cost-effectiveness of new cardiovascular technologies.
Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.

2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.

3) Outcomes research using existing clinical and administrative datasets.

4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction).

936 Total Publications
close
Karen G. Hirsch, MD

Associate Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery
Clinical Focus
Stroke, Traumatic Brain Injury, Cardiac Arrest, Coma, Brain Death, Hypoxic ischemic Brain Injury, Neurocritical Care

72 Total Publications
close
Mark Hlatky, MD

Professor of Health Policy, of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Research Interests
My main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.

423 Total Publications
close
Saraswati Kache

Clinical Professor, Pediatrics - Critical Care
Clinical Focus
Pediatric Intensive Care, Pediatric Critical Care Medicine

24 Total Publications
close
Helena Chmura Kraemer

Professor of Biostatistics in Psychiatry, Emerita
Research Interests
I am interested in the methodology pertinent to dealing with research problems where biological and behavioral interests meet. These interests have been applied not only in psychiatric research, but in those areas of Cardiology, Pediatrics and other fields of medicine in which behavioral research is becoming ever more salient.

481 Total Publications